You just read:

Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis

News provided by

Galmed Pharmaceuticals Ltd.

Sep 26, 2019, 08:00 ET